
Zealand Pharma's Stock Faces Volatility Amid Drug Data, Investors Eye Next Hope
Zealand Pharma's stock dropped significantly due to high dropout rates for its weight loss drug survodutide. While survodutide's peak sales forecasts were cut, investors are now focusing on the company's amylin-based drug, petrelintide, as a potential future growth driver.














